News and Reports
-
connectRN closes $76M financing to support accelerating growth of Healthcare Workforce Platform
8 December 2021Download -
Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines
7 December 2021Download -
Freenome Raises $300M in Series D Financing to Advance Multiomics Platform for Early Cancer Detection
7 December 2021Download -
SWIXX SIGNS NEW ADDENDUM WITH JAZZ; ADDS VYXEOS® LIPOSOMAL FOR POLAND
3 December 2021Download -
NiKang Therapeutics Announces First Patient Dosed in A Phase 1
15 November 2021Download -
SK Biopharmaceuticals enters Greater China out-licensing 6 clinical pipelines to CNS-focused biotech Ignis Therapeutics
11 November 2021Download -
Acrivon Therapeutics Closes Oversubscribed $100 Million Series B Financing to Advance its Innovative Precision Proteomics Platform and Clinical Oncology Pipeline
11 November 2021Download -
SWIXX AND ALBIREO INK PAN-CEE AGREEMENT FOR BYLVAY®
4 November 2021Download -
IO Biotech, Inc. Announces Pricing of Initial Public Offering
4 November 2021Download -
Pyxis Announces Pricing of Upsized Initial Public Offering
8 October 2021Download -
IO Biotech Announces Clinical Collaboration with MSD to Evaluate IO102-IO103 with KEYTRUDA® (pembrolizumab) as First-Line Treatment in Metastatic Melanoma Patients in a Phase 3 Trial
14 September 2021Download -
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
24 June 2021Download -
Ambrx Announces Pricing of Initial Public Offering
18 June 2021Download -
Numab Therapeutics Completes Oversubscribed CHF 100 Million Series C Financing
20 May 2021Download -
Relief and Applied Pharma Research (APR) Sign Binding Term Sheet for Relief to Acquire All Outstanding Shares of APR
4 May 2021Download -
Werewolf Therapeutics Announces Pricing of Upsized Initial Public Offering
30 April 2021Download -
Mineralys Therapeutics Closes $40 Million Series A Funding
6 April 2021Download -
Pyxis Oncology Closes $152 Million Series B Financing to Further Advance Portfolio of Biologics
30 March 2021Download -
IPOs of Instil Bio and Connect Biopharma increase net asset value per HBM share by CHF 4.55 (+1.5%)
22 March 2021Download -
SWIXX SIGNS CEE REGIONAL AGREEMENT WITH JAZZ PHARMACEUTICALS FOR VYXEOS® LIPOSOMAL
15 March 2021Download -
Successful debut on the stock exchange for HBM portfolio company Longboard Pharmaceuticals
15 March 2021Download -
Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform
12 March 2021Download -
Longboard Pharmaceuticals Announces Pricing of Initial Public Offering
12 March 2021Download -
NEURELIS ANNOUNCES CLOSE OF $114 MILLION SERIES D FINANCING ROUND TO ADVANCE NEUROSCIENCE FOCUS
10 March 2021Download -
eGenesis Announces $125 Million Series C Financing
2 March 2021Download